Evidence map›Paper›PMID 34953942›Full record

ReviewSeminars in cancer biology2022

Vimentin and cytokeratin: Good alone, bad together.

Nick A Kuburich, Petra den Hollander, Jordan T Pietz, Sendurai A Mani

Open access · hybridAbstract readReview
In one paragraph

Review in Seminars in cancer biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 187 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. An updated guide to hair follicle stem cell markers and changes in their expression with aging.JID innovations : skin science from molecules to population health · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nick A KuburichDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Petra den HollanderDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Jordan T PietzDepartment of Creative Services, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Sendurai A ManiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Electronic address: smani@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progressionR01CA155243 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MANI, SENDURAI AYYAVOO · 2011 to 2022
$3.2M
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCsR01CA200970 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MANI, SENDURAI AYYAVOO · 2017 to 2021
$2.7M
Training Grant in Cancer BiologyT32CA186892 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2016 to 2020
$1.1M
NCI NIH HHS R01 CA155243NCI NIH HHS R01 CA200970NCI NIH HHS T32 CA186892
6 · The paper itself

Abstract

The cytoskeleton plays an integral role in maintaining the integrity of epithelial cells. Epithelial cells primarily employ cytokeratin in their cytoskeleton, whereas mesenchymal cells use vimentin. During the epithelial-mesenchymal transition (EMT), cytokeratin-positive epithelial cells begin to express vimentin. EMT induces stem cell properties and drives metastasis, chemoresistance, and tumor relapse. Most studies of the functions of cytokeratin and vimentin have relied on the use of either epithelial or mesenchymal cell types. However, it is important to understand how these two cytoskeleton intermediate filaments function when co-expressed in cells undergoing EMT. Here, we discuss the individual and shared functions of cytokeratin and vimentin that coalesce during EMT and how alterations in intermediate filament expression influence carcinoma progression.

Indexed as

Intermediate FilamentsKeratinsCytoskeletonEpithelial-Mesenchymal TransitionHumansVimentinKeratinsVimentinCancer stem cellsCytokeratinEpithelial-mesenchymal transitionIntermediate filamentsVimentin

Identifiers

PMID34953942
PMCPMC9213573
OpenAlexW4200076559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.